rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SLN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
      Nov 12Yahoo FinanceSLN
      Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
      Nov 4Yahoo FinanceSLN
      Silence Therapeutics stock hits 52-week high at 19.62 USD
      Oct 20Investing.comSLN
      Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
      Oct 20Yahoo FinanceSLN
      Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
      Oct 20Yahoo FinanceSLNMRK
      Is Merck KGaA (XTRA:MRK) Undervalued On Silence Therapeutics Deal News?
      Oct 20Yahoo FinanceSLNMRK
      Merck KGaA (XTRA:MRK) Makes A Rare Disease Bet With A Phase 3 Ready siRNA Deal
      Oct 20Yahoo FinanceSLNMRK
      Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?
      Oct 20Yahoo FinanceSLN
      AMZN, CLF, IRON, SLN, EYPT: 5 Trending Stocks Today - Amazon.com (NASDAQ:AMZN)

      Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.

      Oct 20BenzingaEYPTIRONSLNCLF
      Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
      Oct 19Yahoo FinanceSLNMRK
      Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA (SLN)
      Oct 19Seeking AlphaSLNMRK
      Silence Therapeutics Lands a 130% Takeover Premium
      Oct 19Yahoo FinanceSLN
      Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge
      Oct 19Yahoo FinanceSLNMRK
      12 Health Care Stocks Moving In Monday's Intraday Session - Silence Therapeutics (NASDAQ:SLN), SCWorx (NA

      Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock

      Oct 19BenzingaSLN
      Why Is Silence Therapeutics Stock Skyrocketing Monday? - Silence Therapeutics (NASDAQ:SLN), MERCK KGAA by

      Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.

      Oct 19BenzingaSLNMRK
      Silence Therapeutics Agrees to $1.3 Billion Merck KGaA Acquisition at 130% Premium
      Oct 19Yahoo FinanceSLNMRK
      Silence Therapeutics jumps 59% on Merck takeover
      Oct 19Yahoo FinanceSLNMRK
      Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday - Silence T

      U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.

      Oct 19BenzingaIRONSLN
      Why is Silence Therapeutics stock up 125% today?
      Oct 19Investing.comSLN
      Merck KGaA bets on RNAi with $1.3B Silence buyout
      Oct 19Yahoo FinanceSLNMRK
      Silence Therapeutics stock soars 125% on Merck acquisition
      Oct 19Yahoo FinanceSLNMRK
      Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

      Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target’s closing price as of Friday.

      Oct 19WSJSLNMRK
      Silence Therapeutics to be Acquired by Merck KGaA for $20 Per ADS
      Oct 19Yahoo FinanceSLN
      Germany's Merck buys Silence Therapeutics for $1.3 billion
      Oct 19ReutersPTGXSLNMRK
      Merck KGaA to Buy Silence Therapeutics for $1.1 Billion
      Oct 19BloombergSLNMRK
      Merck KGaA to acquire Silence Therapeutics for $1.3 billion
      Oct 19Investing.comSLNMRK
      Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%

      Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.

      Oct 19Barron'sSLNMRK
      Silence Therapeutics Soars 125% on All-Cash $1.3 Billion Merck KGaA Buyout: “Immediate and Certain”
      Oct 19Yahoo FinanceSLN
      Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

      The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

      Oct 14Yahoo FinanceSLN
      Silence Therapeutics (SLN) Upgraded to Buy: Here's Why

      Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Oct 13Yahoo FinanceSLN
      Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma
      Sep 25BarchartPTGXSLN
      Silence Therapeutics at Morgan Stanley conference: divesiran drives focus
      Sep 16Investing.comSLNMS
      Silence Therapeutics at H.C. Wainwright conference: divesiran drives focus
      Sep 15Investing.comSLN
      Silence Therapeutics at Cantor healthcare conference: divesiran advances
      Sep 9Investing.comSLN
      TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
      Sep 2BenzingaSLNTCRX
      Silence Therapeutics to Participate in Three September Investor Conferences
      Sep 2Yahoo FinanceSLN

      This is the newest page. Registered accounts read further back.